The Full Wiki

More info on LY-503,430

LY-503,430: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 625820-83-9
ATC code  ?
Chemical data
Formula C20H25FN2O3S 
Mol. mass 392.49 g/mol
SMILES eMolecules & PubChem
Synonyms LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
Therapeutic considerations
Pregnancy cat.  ?
Legal status Investigational New Medicine
Routes oral

LY-503,430 is an ampakine drug developed by Eli Lilly.[1]

LY-503,430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus and striatum.[2][3] It is orally active and the main application it is currently being developed for is treatment of Parkinson's Disease although it has also been proposed to be useful in the treatment of Alzheimer's Disease, depression and schizophrenia.[4][5]


  1. ^ O'neill, MJ; Murray; Clay; Lindstrom; Yang; Nisenbaum (2005). "LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease". CNS drug reviews 11 (1): 77–96. PMID 15867954. 
  2. ^ Murray, TK; Whalley; Robinson; Ward; Hicks; Lodge; Vandergriff; Baumbarger et al. (2003). "LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease". The Journal of pharmacology and experimental therapeutics 306 (2): 752–62. doi:10.1124/jpet.103.049445. PMID 12730350. 
  3. ^ Ryder, JW; Falcone; Manro; Svensson; Merchant (2006). "Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors". The Journal of pharmacology and experimental therapeutics 319 (1): 293–8. doi:10.1124/jpet.106.105734. PMID 16803862. 
  4. ^ O'neill, MJ; Bleakman; Zimmerman; Nisenbaum (2004). "AMPA receptor potentiators for the treatment of CNS disorders". Current drug targets. CNS and neurological disorders 3 (3): 181–94. PMID 15180479. 
  5. ^ O'neill, MJ; Witkin (2007). "AMPA receptor potentiators: application for depression and Parkinson's disease". Current drug targets 8 (5): 603–20. PMID 17504104. 


Got something to say? Make a comment.
Your name
Your email address